Figure S1



Figure S1 Reporter gene assay of miR-29a-5p interaction

A) Predicted binding sites within the 3'UTR of the 5-LO of miR-29a-5p. **B)** Plasmid construct for the in-vitro analysis based on the pMIR-Report plasmid by Invitrogen®, where the whole 3'UTR of the 5-LO is cloned behind the luciferase gene. **C)** Results of the reporter gene assay performed in Cos-7 cells by co-transfection of pMIR-Report plasmid and mature miRNA with Lipofectamine 2000. The RLU values normalised to the negative control #1 are shown. [Mean + SEM; n=3].

Figure S2



Figure S2. Efficiency of miR-19a antagomir treatment

For determination of the efficiency of the antagomir treatment, the mRNA expression of the verified miT-19a target Cyclin D1 was detected. Shown are the ΔΔCt values of the Cyclin D1 mRNA after miR-19a antagomir treatment normalised to the control antagomir on days three and four. The treatment with the antagomir-19a leads to an increase in the Cyclin D1 mRNA. [RNA values normalised to U48; mean of 3 different patients + SEM].